阿斯利康中国以及阿斯利康两位前高管，被深圳检方提起公诉

Core Viewpoint - AstraZeneca's former global executive vice president and China president, Wang Lei, has been indicted for illegal activities, including the unlawful collection of personal information and illegal trade, which may pose risks to the company's reputation and operations in China [3][4][7]. Group 1: Legal Issues - In November 2025, the Shenzhen prosecutor indicted AstraZeneca China, a former executive vice president, and a former senior employee for unlawful collection of personal information and illegal trade, with no allegations of illegal gains for the company [4][6][7]. - The Shenzhen City Customs Office notified AstraZeneca China in October 2025 of unpaid import taxes totaling RMB 24 million (approximately USD 3.5 million) related to specific drugs [4][6]. - AstraZeneca China voluntarily prepaid the full amount of unpaid import taxes, but if found liable for illegal trade, the company could face fines ranging from one to five times the amount of these taxes [5][6]. Group 2: Company Performance - Despite the legal challenges, AstraZeneca's revenue in China reached USD 6.654 billion in 2025, marking a 4% year-on-year increase and accounting for 11% of the company's global revenue [7]. - The growth rate in China is lower than the global revenue growth rate of 8%, indicating potential challenges in maintaining market momentum [7]. - AstraZeneca plans to invest over RMB 100 billion (USD 15 billion) in China by 2030 to expand its pharmaceutical production and R&D capabilities [7].